Aptiganel
Aptiganel (Cerestat; CNS-1102) is an unsuccessful drug candidate which acts as a noncompetitive NMDA antagonist, and that was under development by Cambridge Neuroscience, Inc as a treatment for stroke. It has neuroprotective effects and was researched for potential use in the treatment of stroke, but despite positive results in animal studies, human trials showed limited efficacy, as well as undesirable side effects such as sedation and hallucinations, and clinical development was ultimately not continued.
Link from a Wikipage to another Wikipage
primaryTopic
Aptiganel
Aptiganel (Cerestat; CNS-1102) is an unsuccessful drug candidate which acts as a noncompetitive NMDA antagonist, and that was under development by Cambridge Neuroscience, Inc as a treatment for stroke. It has neuroprotective effects and was researched for potential use in the treatment of stroke, but despite positive results in animal studies, human trials showed limited efficacy, as well as undesirable side effects such as sedation and hallucinations, and clinical development was ultimately not continued.
has abstract
Aptiganel (Cerestat; CNS-1102) ...... CeNeS Pharmaceuticals in 2000.
@en
أبتيجانيل (بالإنجليزية: Aptiga ...... يستخدم لعلاج السكتة الدماغية.
@ar
CAS number
137159-92-3
ChEMBL
FDA UNII code
46475LV84I
PubChem
Wikipage page ID
18,485,979
page length (characters) of wiki page
Wikipage revision ID
963,077,016
Link from a Wikipage to another Wikipage
ATC prefix
none
@en
CAS number
ChEMBL
ChemSpiderID
IUPAC name
legal status
Uncontrolled
@en
PubChem
SMILES
CCC1=CCNCN
@en
StdInChIKey
BFNCJMURTMZBTE-UHFFFAOYSA-N
@en
UNII
Verifiedfields
changed
@en
verifiedrevid
477,350,281
wikiPageUsesTemplate
hypernym
comment
Aptiganel (Cerestat; CNS-1102) ...... was ultimately not continued.
@en
أبتيجانيل (بالإنجليزية: Aptiga ...... يستخدم لعلاج السكتة الدماغية.
@ar
label
Aptiganel
@en
أبتاغانيل
@ar